Metabolic Syndrome

Overview

Metabolic syndrome is a cluster of conditions (central obesity, hypertension, hyperglycemia, dyslipidemia, insulin resistance) that dramatically increase cardiovascular and diabetes risk. Peptide therapy targets multiple components simultaneously: GLP-1/GIP agonists address glucose and weight, mitochondrial peptides improve insulin sensitivity, and GH axis peptides reduce visceral adiposity. This is one of the highest-impact areas for peptide intervention.

Recommended Peptides

MOTS-C – mitochondrial-derived peptide that improves insulin sensitivity, increases fatty acid oxidation, and acts as an exercise mimetic; particularly effective for metabolic syndrome components
Retatrutide – triple agonist (GLP-1/GIP/glucagon); addresses obesity, hyperglycemia, and dyslipidemia simultaneously; most comprehensive metabolic peptide
Semaglutide – GLP-1 agonist; reduces cardiovascular events in addition to weight and glucose control; clinically proven
Tirzepatide – dual GLP-1/GIP agonist; superior glycemic and weight control vs semaglutide; FDA-approved for T2D and obesity
5-Amino-1MQ – NNMT inhibitor; improves metabolic rate, reduces fat accumulation, and activates AMPK pathways
NAD+ – restores NAD+/NADH ratio critical for insulin signaling and mitochondrial function; subcutaneous preferred
Tesamorelin – GHRH analogue that reduces visceral fat (the most metabolically harmful adipose depot) and improves lipid profiles

Protocols

Related Conditions

Research Summary

MOTS-C promotes metabolic homeostasis via AMPK activation and folate cycle inhibition (PMID-25738459) and reduces myostatin/muscle atrophy in HFD mice (PMID-33554779). 5-Amino-1MQ dose-dependently improved glucose tolerance and insulin sensitivity while reducing liver fat (PMID-39161060). Retatrutide addresses obesity, hyperglycemia, and dyslipidemia simultaneously as a triple agonist (PMID-37366315). Semaglutide SELECT trial demonstrated 20% MACE reduction independent of diabetes (PMID-37952131).

#condition #metabolic-system